Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
Three years ago, only about a quarter of the nation’s large employers were very confident they would have a health plan in 10 years. That number has now risen to 65 percent.
Court allows state attorneys general to join a pending legal challenge to keep billions in subsidies flowing to consumers and insurers, despite the Trump administration’s resistance.
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
The Senate draft bill released Thursday to replace the Affordable Care Act risks creating a high-cost ghetto for those with preexisting conditions or long-term sickness, experts say.
Experts say the loopholes would allow states to bypass some protections for people with preexisting conditions.
Expertos en políticas de salud que han analizado el texto del proyecto de salud del Senado, aseguran que la legislación no siempre garantizaría la atención de personas con condiciones preexistentes.
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
There are many ways beyond legislative repeal for the Trump administration and congressional Republicans to unravel the Affordable Care Act.